Stock’s Buzzers: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) & Spartan Motors, Inc. (NASDAQ:SPAR)

6

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States.

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)’s Financial Overview

Paratek Pharmaceuticals, Inc. (NASDAQ) surged 1.79% yesterday to close its trading session at $6.24. The company has 1 year Price Target of $25.36. Paratek Pharmaceuticals, Inc. has 52-Week high of $18.1 and 52-Week Low of $4.5. The stock touched its 52-Week High on 18.40 and 52-Week Low on 4.50. The stock traded with the volume of 233372 shares yesterday. The firm shows the market capitalization of $197.87 Million.

Paratek Pharmaceuticals, Inc. (NASDAQ) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $-1.01/share against the analyst consensus estimate of $-0.84/share. The difference between the actual and expected EPS is $-0.17 a share with a surprise factor of -20.2%.

The firm is trading with SMA20 of 10.77 Percent, SMA50 of -5.93 Percent and SMA200 of -34.91 percent. Paratek Pharmaceuticals, Inc. has P/S value of 38.05 while its P/B value stands at 3.43. Similarly, the company has Return on Assets of -44.6 percent, Return on Equity of -132.5 percent and Return on Investment of -60.2 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 0 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 1.5 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 11 analysts offering 12-month price forecasts for Paratek Pharmaceuticals Inc have a median target of 22.00, with a high estimate of 56.00 and a low estimate of 12.00. The median estimate represents a +252.56% increase from the last price of 6.24.

Paratek Pharmaceuticals, Inc. is estimated to report earnings on 03/07/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 8 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.6. The reported EPS for the same quarter last year was $-0.78.

Spartan Motors, Inc. (NASDAQ:SPAR)

Spartan is a leading designer, engineer and manufacturer of custom heavy-duty chassis. The Company’s chassis consist of a frame assembly, engine, transmission, electrical systems, running gear (wheels, tires, axles, suspension and brakes) and, for some applications, a cab. The Company’s customers are original equipment manufacturers (OEMs) who complete their vehicle product by mounting the body or apparatus on a Spartan chassis.

Spartan Motors, Inc. (NASDAQ:SPAR)’s Financial Outlook

The 3 analysts offering 12-month price forecasts for Spartan Motors Inc have a median target of 12.00, with a high estimate of 16.00 and a low estimate of 12.00. The median estimate represents a +46.34% increase from the last price of 8.20.

Spartan Motors, Inc. is estimated to report earnings on 03/07/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.04. The reported EPS for the same quarter last year was $0.11.

According to Zacks Investment Research, Spartan Motors, Inc. has a Consensus Recommendation of 1. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock declined -0.36% and closed its last trading session at $8.2. The company has the market capitalization of $289.46 Million. The stock has 52-week high of $19.45 and 52-Week low of $6.7. The firm touched its 52-Week high on 19.45 and 52-Week low on 6.70. The company has volume of 164756 shares. The company has a total of 35.3 Million shares outstanding.

Spartan Motors, Inc. (NASDAQ) in the last quarter reported its actual EPS of $0.17/share where the analyst estimated EPS was $0.25/share. The difference between the actual and Estimated EPS is $-0.08. This shows a surprise factor of -32 percent.

The company has YTD performance of 13.42 percent. Beta for Spartan Motors, Inc. stands at 1.3 while its ATR (average true range) is 0.37. The company has Weekly Volatility of 4.76%% and Monthly Volatility of 4.88%%.

Spartan Motors, Inc. has distance from 20-day Simple Moving Average (SMA20) of 9.3%, Distance from 50-Day Simple Moving Average of 4.26 percent and Distance from 200-Day Simple Moving Average of -38.62%.

The Company currently has ROA (Return on Assets) of 4.8 percent, Return on Equity (ROE) of 8.8 Percent and Return on Investment (ROI) of 10.2% with Gross margin of 13 percent and Operating & Profit margin of 2.6% and 2% respectively.

SHARE